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NEURAL REGENERATION RESEARCH

a PERSPECTIVE

Recent advances on the role of long
non-coding RNAs in Alzheimer's
disease
Dementia is a progressive cognitive impairment that affects the activities
of daily living. Alzheimer's disease (AD) is the most common form of the
dementia worldwide accounting for 60-80% of all dementia cases. With an
estimated cost exceeding $290 billion in the USA, understanding and development of future therapeutic strategies is vital. In this perspective, we will
be examining the current thinking of AD research and therapeutic strategies, while proposing a possible new direction for diagnosis, understanding,
and treatment targets. Non-coding RNA accounts for the largest population of the human transcriptome. Long noncoding RNA (lncRNA) is a
recent molecule of interest in the biomedical research which is non protein
coding and is of length greater than 200 nucleotides. LncRNAs have been
shown to play diverse roles within the cells such as posttranscriptional and
posttranslational regulation, chromatin modulation, and protein complex
organization. Given the flexible and diverse role in disease pathophysiology,
lncRNAs may serve as novel therapeutic targets for diagnosis and treatment.
Evidently, recent studies showed that dysregulation of lncRNA influences
the clinical course of tumorigenesis, neurological disorders, cardiovascular
disease, diabetes, and acquired immunodeficiency syndrome (Kazimierczyk
et al., 2020) . This indicates that lncRNA can provide a unique avenue of research and possible therapeutic targets in AD.

Current AD research: AD is the most common form of dementia, characterized by progressive neuronal death associated with neuropathological
findings of neurofibrillary tangles and senile plaques. Despite considerable
advances in the knowledge of AD pathogenesis, we know little about how to
prevent or delay the ongoing neurodegenerative process. Therefore, a deeper
understanding of the molecular mechanisms involved in AD pathogenesis is
essential, which would contribute to the development of a novel therapeutic
target. The vast majority of AD occurs on a seemingly sporadic basis. While
both genetic and environmental factors may drive sporadic AD, the £4 allele
of apolipoprotein E gene is a major genetic risk factor for the AD development. However, it has been found that a familial form of AD is driven by
mutations in amyloid precursor protein (APP), presenilin I (PSENI), and
presenilin 2 (PSEN2), which occurs much earlier than sporadic AD, between
the ages of 30 and 50 years. Mutations in the genes APP/PSENI/PSEN2 for
familial form of AD or dysfunction in apolipoprotein E leads to an unfavorable accumulation of the amyloid beta (AP) peptide. This eventually leads to
widespread neuronal/synaptic dysfunction and ultimately dementia (Selkoe
and Hardy, 2016). Unfortunately, attempts to ameliorate the disease course
by removing AP or reducing its production have been largely unsuccessful. The failure of drugs targeting AP deposition in the brain has fueled an
increasing interest in alternative disease-causing mechanisms. The recent
progress of deep-transcriptome sequencing and genome-wide analyses have
identified several dysregulated lncRNAs in AD, but the expression patterns,
interacting proteins, and biological functions of these lncRNAs in AD remain largely unexplored. Thus, understanding how lncRNAs regulate neuronal function in the brain may allow for the development of effective therapies for AD and related neurodegenerative diseases. Interestingly, lncRNA
biology is the rapidly emerging area of focus in biomedical research field. It
is evident from the exponential increase of published articles on lncRNA.
As searched on PubMed, lncRNA and cancer showed 34 articles in 2010 and
3174 in 2019. Evidently, lncRNA in AD has gained some attention with 85
articles on PubMed in 2019. This shows lncRNA as a potential and novel target in AD, which needs to be explored for its mechanism and etiology.
LncRNAs in AD: Once considered transcriptional noise, lncRNAs are associated with specialized functions in specific cell types. They are predominantly located in the nucleus helping in one of their functions of epigenetic
regulation (Luo and Chen, 2016) . With diverse roles, cell specific functions,
and dysregulation linked to cancer, epilepsy, cardiovascular, neurodegenerative, and genetic diseases, it stands to reason that lncRNA would confer
promoting or inhibiting effects in the development of AD, similar to its
contribution in other diseases (Luo and Chen, 2016). Although, the role of
lncRNAs in AD are fairly studied over the past few years, the mechanisms
of its involvement in neurodegeneration and cognitive impairment are unknown. Recently, several lncRNAs, BACEI-AS, SIA, 17A, NDM29, BC200,

MALATI, BDNF-AS and NAT-Radl8 have been shown to play a role in
AD. These lncRNAs regulate synaptic plasticity, APP processing, tau phosphorylation and inflammation, major causal agents in AD (Figure I; Cortini et al., 2019). In addition, it has been suggested that lncRNAs also interact
with miRNAs and regulate a broad range of biological processes through
their crosstalk with miRNAs. Besides that, a recently identified lncRNA
EBF3-AS plays a role in promotion of neuronal apoptosis in a murine model of AD and was abnormally expressed in the brains of AD patients (Gu et
al., 2018) . The conserved anti-sense noncoding RNA P-secretase-1 (BACEIAS) is highly expressed in the brains of AD patients and mouse models
of AD and drives feed-forward regulation of BACEI (Faghihi et al. 2008).
BACE!-AS increases in response to cell stressors, suggesting its role in overall progression of AD. A study by Zhang and coworkers demonstrated that
silencing ofBACE!-AS by short interfering RNA reduces the production of
AP 1-42 oligomers in cellular system and improves cognitive function through
regulation of BACEI, and tau phosphorylation in in vivo (Zhang et al.,
2018). Therefore, it is conceivable that BACEI-AS could serve as a potential
biomarker for diagnosis and therapeutic target for the treatment of AD.
Similarly, lncRNAs SIA, 17A, and NDM29 have been shown to increase AP
abundance (Luo and Chen, 2016). The lncRNA SIA has been shown in a
recent study to drive a splicing shift in variant A of SORLI. The decrease in
SORLI variant A leads to an impaired processing of APP leading to increase
in the formation of Ap. Neuroblastoma differentiation marker 29 (NDM29)
drives neuroblastoma cell differentiation to nonmalignant neuron-like phenotypes. In cells dependent upon NDM29 maturation, there is an increased
synthesis of APP and subsequent AP formation and secretion (Cortini et al.,
2019). The lncRNA BC200 regulates cell viability and apoptosis via modulating the expression of BACEI and its level is significantly upregulated
in the AD patients (Mus et al., 2007). Increased expression of NAT-Radl8
leads to dysregulation of DNA Repair mechanism leading to an increase in
neuron sensitivity to apoptosis and AD progression (Luo and Chen, 2016).
LncRNA MALATI was originally identified in lung cancer and found to
promote cell proliferation and metastasis in various cancers such as lung,
ovarian, and pancreatic cancer. However, in a recent study inhibition of
MALATI has been shown to inhibit neuron apoptosis and promote neurite outgrowth (Ma et al., 2019) . This evidence suggests that MALATI can
provide a new route in the understanding of the mechanism of AD disease
progression and provide new therapeutic targets. LncRNA BDNF-AS plays
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Figure I A schematic diagram representing the possible lncRNA
neuroprotective function in Alzheimer's disease.
LncRNA might function as Decoy and/or Scaffold to sequester secretase
enzyme and hence hinders enzyme function, decreasing amyloid beta (AP)
aggregation. It can sequester kinases to decrease tau hyperphosphorylation.
LncRNA can also decrease neurofibrillary tangles burden phosphorylated,
by keeping hyperphosphorylated tau proteins apart. APP: Amyloid precusor
protein; AP: amyloid beta; lncRNA: long non-coding RNA.
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an important role in the regulation of BDNF protein expression. Inhibition
of BDNF-AS increases mRNA levels of BDNF, enhances protein levels of
BDNF and triggers neuronal differentiation. Given the role ofBDNF in AD
and other neurological disorders, pharmacological inhibitors of BDNF-AS
may have significant therapeutic potential in the treatment of AD. These
findings provided proof-of-concept evidence and support for the potential
roles of lncRNA in AD pathogenesis. Understanding the molecular mechanisms underlying lncRNA dysregulation in AD may provide new insights
into AD pathophysiology and open new therapeutic avenues.
Novel biomarkers: Early diagnosis of any disease more often leads to better
outcomes. The unique aspects of lncRNA make it a leading candidate as a
diagnostic and/or prognostic biomarker. LncRNA has been mostly characterized in cancer and has also been shown to be a biomarker candidate
in other diseases too. While recent studies on lncRNAs have shown them
to be aberrantly expressed, and some appear to be cancer specific. The specific expression, stability in bodily fluids, and increased expression often
correlating to the severity of the disease making lncRNAs an attractive candidate for non-invasive screening. LncRNAs are already in clinical trials as
biomarkers. LncRNA PCA3 is one of these, due to its high levels and specificity to prostate cancer along with its detectable limits in urine (Bhan et
al., 2017). HOTAIR circulation has been suggested as a possible diagnosis's
marker for breast cancer. In addition, a recent study by Tan and colleagues
have demonstrated that HOTAIR is a peripheral biomarker for glioblastoma multiforme patients (Tan et al., 2018). The expression of BACEl-AS
is upregulated in blood samples from AD patients, indicating BACEl-AS
may serve as a plausible biomarker for AD (Zhang et al., 2018). Similarly,
increased lncRNA SIA expression has been detected in the plasma of AD
patients, suggesting lncRNA SIA in plasma could be used as a potential
diagnostic and prognostic biomarker for AD. MALATl expression can be
used as marker for lung cancer. Interestingly, a study by Yoa et al. (2016) reported decreased lncRNA MALATl levels in the cerebrospinal fluid of AD
patients compared with the control group, suggesting lncRNA MALATl
monitoring in cerebrospinal fluid could serves a diagnostic marker for AD.
The flexibility demonstrated in cancer and other neural diseases along with
evidence suggesting lncRNA playing a key role in the development of AD
indicate, that lncRNA might provide effective candidates for non-invasive
screening for AD.
Conclusion: The last 25 years of AD research and therapeutic development
has been focused on understanding and preventing the accumulation of
toxic A~. The amyloid cascade hypothesis has provided a strong backbone
that has led to great leaps in knowledge when it comes to AD. This backbone has also led to stagnation in AD diagnosis and therapeutics. This is
evident in the non-existence of disease modifying therapeutic options and
earlier detection of AD. LncRNA provides a novel route of research for the
development of new therapies and diagnostic markers for AD. Recent studies have provided important insights of the biological function and clinical
relevance of lncRNAs in AD. Although, there is increasing recognition that
lncRNAs have been implicated in AD pathogenesis, but it remains unknown
how they influence AD development and progression. Understanding the
regulatory function and molecular mechanisms of lncRNAs in AD pathophysiology will fuel the development of innovative diagnosis strategies and
potential therapeutic targets. LncRNA is already beginning to be uncovered as a potential key player in the development of AD as shown in the
studies mentioned above. However, it is not just a promotive agent in AD
as demonstrated by MALATl expression, leading to inhibition of neuron
apoptosis and neurite growth. Moreover, findings on the role of lncRNAs
in cancers and glioblastoma may shed new light on understanding of molecular mechanisms of lncRNA in AD. With AD the most common form
of dementia, and more than triple the current estimated 44 million people
to live with dementia worldwide by 2050, there is an urgent need for new
therapies and diagnostic tools for AD. Undoubtedly, activators or inhibitor
of lncRNAs will provide a potential and novel strategy for the treatment of
AD. Interestingly, antisense oligonucleotides (ASOs) targeting aberrantly
expressed lncRNAs may represent a feasible treatment for AD. Development of specific ASOs downregulating BACEI-AS, SIA, 17A, NDM29 and
BDNF-AS may represent novel and potential therapeutic strategy in order
to regulate A~ production, inflanunation and tau phosphorylation in AD.
However, the major challenge in using ASOs in neurodegenerative disorders is the poor bioavailability, susceptible nuclease degradation nature, and
limited blood-brain barrier permeability. EVs, small nanovesicles, also frequently referred to as exosomes, recently been recognized as potential drug
delivery systems for therapeutic interventions. It is desirable to load ASOs
targeting lncRNAs in EVs and examine their therapeutic effects on AD-related neuropathology and cognitive function. Furthermore, lncRNAs may
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be used as potential biomarker for clinical assessment of AD stages, as their
abnormal expression pattern can be easily detected in plasma or cerebrospinal fluid of AD patients. The use of lncRNAs as diagnostic and prognostic
markers has already been exploited in the cancer research but more research
is needed to establish lncRNAs as biomarker for AD patients. In conclusion, the role of lncRNAs in the AD pathogenesis is largely unexplored and
understanding the molecular mechanisms of lncRNAs in AD will uncover
more avenues to early diagnosis and effective therapies.
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